Officials with Gaithersburg-based Novavax Inc. said Wednesday they will lay off 30 percent of their workforce as they scramble to rework the company’s pipeline following a failed phase 3 clinical trial of its lead respiratory syncytial virus vaccine candidate for older adults.
During a third-quarter earnings call Wednesday, CEO Stanley Erck told shareholders the company will focus on its RSV vaccine for infants via maternal immunization. The company is also working to re-examine its RSV vaccine…
Officials with Gaithersburg-based Novavax Inc. said Wednesday they will lay off 30 percent of their workforce as they scramble to rework the company’s pipeline following a failed phase 3 clinical trial of its lead respiratory syncytial virus vaccine candidate for older adults.
During a third-quarter earnings call Wednesday, CEO Stanley Erck told shareholders the company will focus on its RSV vaccine for infants via maternal immunization. The company is also working to re-examine its RSV vaccine…